Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYT107 in HIV-infected immunological non-responders
NCT01241643Phase 2Terminated
- Sponsor
- Cytheris SA
- Start
- Sep 2010
- Primary completion
- Jun 2013
- Modality
- Cytokines & Interferons
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of recombinant human interleukin-7 in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Cytheris SA. Primary endpoints: CD4 T-lymphocyte Counts at 24 months and Safety of repeated cycles of CYT107 at 24 months. Started Sep 2010; status: terminated.
02
Drugs
recombinant human interleukin-7
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01241643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01241643.